Your search for prostate returned 38 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Da Hee Han, PharmD remove

Your search for prostate returned 38 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

Xtandi Plus ADT Beneficial in Metastatic Hormone-Sensitive Prostate Cancer

ARCHES (NCT02677896) is a randomized, double-blind placebo-controlled, multinational trial that assigned 1150 patients with mHSPC to either Xtandi 160mg daily or placebo plus ADT (luteinizing hormone-releasing hormone (LHRH) agonist/antagonist or bilateral orchiectomy).

Zytiga Approved for Metastatic High-Risk Castration-Sensitive Prostate Cancer

The FDA approval was supported by results from the Phase 3 multinational, multicenter, randomized, double-blind, placebo-controlled LATITUDE trial (N=1,199) which evaluated Zytiga 1000mg once daily in combination with prednisone 5mg once daily vs placebo in newly diagnosed, metastatic high-risk CSPC patients who had not received prior cytotoxic chemotherapy.

USPSTF Drafts Prostate CA Screening Recommendations

The USPSTF performed a systematic review of the existing evidence and concluded that the potential benefits and harms of prostate-specific antigen (PSA)-based screening are "closely balanced" in men aged 55-69 years.

New Oral Tx Approved for Males With Certain Types of Hypogonadism

The Food and Drug Administration (FDA) has approved Jatenzo (testosterone undecanoate; Clarus Therapeutics) capsules for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: congenital or acquired primary hypogonadism or hypogonadotropic hypogonadism.